

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Levinson Mitchell E.</u>			2. Issuer Name and Ticker or Trading Symbol <u>PULSE BIOSCIENCES, INC. [PLSE]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Strategy Officer		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>09/24/2024</u>					
3957 POINT EDEN WAY			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
(Street)								
<u>HAYWARD</u>	<u>CA</u>	<u>94545</u>						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/24/2024		X ⁽¹⁾		3,000	A	\$11 ⁽²⁾	93,880	D	
Common Stock	09/24/2024		X ⁽¹⁾		1,240	A	\$11 ⁽²⁾	21,240	I	Spouse
Common Stock	09/24/2024		X ⁽¹⁾		322	A	\$11 ⁽²⁾	8,321	I	Immediate Family Member 1
Common Stock	09/24/2024		X ⁽¹⁾		322	A	\$11 ⁽²⁾	8,421	I	Immediate Family Member 2
Common Stock	09/24/2024		X ⁽¹⁾		322	A	\$11 ⁽²⁾	8,521	I	Immediate Family Member 3

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Warrant (right to buy)	\$11	09/24/2024		X ⁽¹⁾			1,500	07/03/2024	07/03/2029	Common Stock	1,500	(1)(2)	0	D	
Warrant (right to buy)	\$11	09/24/2024		X ⁽¹⁾			1,500	07/03/2024	07/03/2029	Common Stock	1,500	(1)(2)	0	D	
Warrant (right to buy)	\$11	09/24/2024		X ⁽¹⁾			620	07/03/2024	07/03/2029	Common Stock	620	(1)(2)	1	I	Spouse
Warrant (right to buy)	\$11	09/24/2024		X ⁽¹⁾			620	07/03/2024	07/03/2029	Common Stock	620	(1)(2)	1	I	Spouse
Warrant (right to buy)	\$11	09/24/2024		X ⁽¹⁾			161	07/03/2024	07/03/2029	Common Stock	161	(1)(2)	0	I	Immediate Family Member 1
Warrant (right to buy)	\$11	09/24/2024		X ⁽¹⁾			161	07/03/2024	07/03/2029	Common Stock	161	(1)(2)	0	I	Immediate Family Member 1
Warrant (right to buy)	\$11	09/24/2024		X ⁽¹⁾			161	07/03/2024	07/03/2029	Common Stock	161	(1)(2)	0	I	Immediate Family Member 2

